Prothena Corporation plc


Market Cap$1.53B

Compare Prothena plc

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Prothena Corporation plcProthena Corporation plc-20.90%-12%13.5-
marketMarket Avg49.51.28%13%6.20.1
HealthcareHealthcare Avg31.91.26%18%7.50.9

Current Fair Value

46.5% upside

Undervalued by 46.5% based on the discounted cash flow analysis.

Share Statistics

Market cap$1.53 Billion
Enterprise Value$859.64 Million
Dividend Yield$0.0 (0.0%)
Earnings per Share$-1.38
Outstanding Shares53,665,349
Avg 30 Day Volume811,463


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-20.91
Price to Sales13.48
Price to Book Ratio2.45
Enterprise Value to Revenue6.1
Enterprise Value to EBIT-7.63
Enterprise Value to Net Income-12
Total Debt to Enterprise0
Debt to Equity0

Revenue Sources

No data

ESG Score

No data

About Prothena Corporation plc

7 employees
CEO: Gene Kinney

Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapeutics with the potential to change the course of devastating neurodegenerative and r...